The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Shanshan Xu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst
: Regarding BNT162, that's the COVID-19 vaccine, among S, M, E, N proteins, what could be your target? And are you thinking about receptor binding
domains? And you also mentioned that you saw neutralizing antibodies generated in the BNT162 preclinical study. Can you share with us, which
epitopes you observed for these neutralizing antibodies? And do you think titer of neutralizing antibodies can serve as surrogate clinical efficacy
Question: Shanshan Xu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst
: Okay. And another question regarding the RNA format and also the delivery formulation. So mod RNA, that's the modified RNA, that is the mRNA
format you used in your Zika vaccine. To us, it is not highly immunogenic. Can you tell us what is the scientific rationale of using it in infectious
disease vaccine? And also for your delivery formulation, the lipid nano particle, LNP, you saw that with this delivery technique, it was modified to
without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
affiliated companies.
MARCH 31, 2020 / 12:00PM, BNTX.OQ - Full Year 2019 BioNTech SE Earnings Call
shift the immune response more towards Th2 cells, not Th1 cells. Can you share us -- with us what modifications have been done on this LNP
formulation to increase Th2 activation?
Question: Arlinda Anna Lee - Canaccord Genuity Corp., Research Division - Analyst
: First on the COVID vaccine. You mentioned that you were working with the German, Chinese and U.S. governments. Wondering if you could provide
some color on your conversations and maybe your strategy on potentially manufacturing at risk. Secondly, on -- we had the chance to see sample
cancer care changes during COVID. And I was wondering if you could comment on modifications to your clinical trials or enrollment criteria. And
also, you're doing a lot of biomarker studies. I'm wondering if some of these assays can be done on archival samples and how that might be affected.
Question: Arlinda Anna Lee - Canaccord Genuity Corp., Research Division - Analyst
: Great. And maybe just following up on your oncology pipeline. Just -- can you -- since biopsy volumes are down, I'm just curious if the enrollment
criteria that you have in place enables use of archival tissue. And how you're collecting biomarker data for your oncology trials, collecting and
processing? And then maybe lastly, can you talk about your strategy for your cytokine pipeline?
|
